Drugs investigated in PsA randomised controlled trials published in 2015–2018
| Therapeutic compound | Articles/abstracts (n) | Drug target | Population |
| Biological DMARDs | |||
| Golimumab | 1 | TNF | csDMARD/NSAID-IR |
| Etanercept | 1 | MTX+DMARD-naive | |
| Adalimumab biosimilar (CT-P13) | 1 | csDMARD-IR | |
| Etanercept biosimilar (CHS-0214) | 1 | csDMARD-IR | |
| Ixekizumab | 10 | IL-17A | csDMARD-IR/TNFi-IR |
| Secukinumab | 5 | NSAID-IR/mixed csDMARD/TNFi-IR | |
| ABT-122 | 1 | TNF/IL-17A | csDMARD/TNFi-IR |
| Ustekinumab | 1 | IL-12/23 | Patients with active enthesitis |
| Risankizumab | 1 | IL-23–19p | NSAID/csDMARD/TNFi-IR |
| Guselkumab | 1 | csDMARD/TNFi-IR | |
| Clazakizumab | 1 | IL-6 | NSAID/csDMARD-IR |
| Abatacept | 1 | CD80/86 | csDMARD/TNFi-IR |
| Targeted synthetic DMARDs | |||
| Apremilast | 5 | PDE4 | csDMARD-IR/TNFi-IR/csDMARD-naive |
| Tofacitinib | 2 | JAK-1/2/3 | csDMARD-IR/TNFi-IR |
| Filgotinib | 1 | JAK-1 | csDMARD-IR |
csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IL, interleukin; IR, insufficient responders; JAK, Janus kinase; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PDE4, phosphodiesterase-4; PsA, psoriatic arthritis; TNF, tumour necrosis factor; TNFi, TNF inhibitor.